• The established and most prominent method of visualizing bladder cancer, white light, lacks the clarity needed to detect finer margins of tumors, which increases the likelihood of recurrence
• The more recent, improved method, blue light, provides clarity yet introduces cost barriers to adoption
• Imagin Medical’s i/Blue Imaging(TM) System combines the best of both methods, clarity and real-time visualization at a lower cost
• The system is highly adaptable to current endoscopic instruments, making it easy and affordable to implement

For over 30 years, the standard of visualizing bladder cancer during surgery has been white light illumination through an endoscopic procedure called a cystoscopy. When performing a cystoscopy, the surgeon uses the scope and white light to identify and remove the tumors that protrude above the bladder. Therein lies the problem, as the finer edges that need to be resected are not always clearly defined and tumors that lay flat against the bladder wall are often not visible using this technology. This inability to resect completely may contribute to the over 50% recurrence rate of bladder cancer.

While these limitations can be successfully overcome with the use of blue light and an imaging agent, this type of illumination has the drawback of not showing the cancer in real time. This requires surgeons to switch between white and blue light, making the procedure more challenging.

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on changing the standards of visualizing cancer during minimally invasive procedures, is intent on addressing these issues through its innovative technology that has the potential to revolutionize the current standard of care for bladder cancer patients. Imagin Medical’s i/Blue Imaging(TM) System eliminates the need to switch between the white and the blue light images by displaying both images side-by-side on a single screen.

The system is based on advanced optics and light sensors and uses patented ultrasensitive imaging technology. It therefore enables better visualization of tumors and margins, allowing for a more accurate resection.

The control unit is state-of-the-art, featuring a dual-wavelength light source, two-channel camera control unit, data recorder, and power supply. Simultaneous white and blue light illumination of the bladder allows for the side-to-side monitor images.

Additionally, Imagin Medical’s system is adaptable to most endoscopes already being used in hospitals. That means healthcare units that want to convert to the i/Blue Imaging(TM) System would not require new endoscopic equipment, resulting in cost savings.

The primary focus of Imagin Medical’s i/Blue Imaging(TM) System is bladder cancer, the sixth most prevalent type of cancer in the United States with one of the highest recurrence rates. The technology has the potential for use in other minimally invasive procedures, with plans already in motion to implement this system for multiple endoscopic procedures in the future, including laparoscopic, colorectal and thoracic procedures that use a variety of contrast dye agents and illumination sources.

Imagin Medical has made the transition from the development stage to manufacturing by contracting the services of Lighthouse Imaging, an FDA-registered and ISO 13485:2016-certified manufacturer, to accelerate production.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.